Invention, development, and worldwide approval of ELIGARD® (leuprolide acetate for injectable suspension) for the palliative treatment of advanced prostate cancer has established TOLMAR Pharmaceuticals as a leader dedicated to the urology community, providers, and patients.
TOLMAR is dedicated to working in partnership with the urology community, its providers, and most importantly, its patients. Passion fueled the invention, development, and advancement of ELIGARD, and it is passion that guides our commitment to providing the highest level of support to the urology community and patients with prostate cancer. Our highly experienced, commercial leadership team and specialty sales force embody dedication with purpose.
TOLMAR is also a leader in Dermatology products and dedicated to developing and manufacturing the highest quality products for our commercial partners. TOLMAR is a fully integrated company focused on the development, approval, and commercialization of specialty pharmaceutical products, including a line of generic dermatology products where TOLMAR is an established leader, and specialty injectable oncology products. TOLMAR has 24 FDA-approved products. At TOLMAR, it is our mission to develop innovative pharmaceutical solutions to serve patients in need. TOLMAR research scientists, chemists, and engineers have developed an extensive portfolio of pharmaceutical products, including a broad line of dermatology products, and ELIGARD for the palliative treatment of advanced prostate cancer. TOLMAR is dedicated to advancing our pipeline of products and expanding our portfolio to serve important patient medical needs.
TOLMAR Pharmaceuticals is based in Lincolnshire, Illinois, with TOLMAR’s product development and manufacturing facilities based in Fort Collins, Colorado. – less